Bora Biologics, a division of CDMO Bora Pharmaceuticals, will support DotBio, a biopharmaceutical company specializing in next-gen antibody therapies, in the development and manufacture of DotBio’s lead asset, a novel tri-specific antibody, DB007, against undisclosed cancer targets.

Bora will support chemistry, manufacturing, and controls (CMC) strategy through to clinical development from its 48,400-sq.-ft. center of excellence in Zhubei, Taiwan.

“Bora Biologics offers a tailored development and manufacturing plan that provides end-to-end support for our client’s development programs,” said Bobby Sheng, Chairman and CEO of Bora Group. “With operations up and running in Zhubei, Bora’s team of experts are ready to deliver high-yield processes together with the sophisticated program management capabilities necessary to successfully develop even the most challenging molecules.”

Ignacio Asial, Ph.D., Founder and CEO of DotBio said, “We chose Bora Biologics as our development partner because of its expertise in early-phase biologics development and solid track record in high-yield manufacturing of multi-specific antibody molecules. Bora’s early-clinical manufacturing facilities in Taiwan align perfectly with our current IND-development stage, while their large-scale, commercial-stage manufacturing and fill-and-finish facilities in the United States will support our goal to treat patients globally. I am thrilled to be working hand-in-hand with one of the best CDMO partners in Asia.”

Bora Biologics’ facility in Zhubei provides early-stage discovery research support, lead candidate screening, in vitro assays, and biochemical/physical assays, as well as preparation and purification of complex proteins, and monoclonal, bispecific and multi-specific antibodies and other recombinant proteins for research purposes.